论文部分内容阅读
目的观察瑞舒伐他汀钙对糖尿病患者血脂异常的疗效及对高敏C反应蛋白(hs-CRP)和脂联素的影响。方法观察238例糖尿病伴有血脂异常的患者,其中治疗组119例,在严格控制血糖和低脂饮食的基础上,给予瑞舒伐他汀钙10 mg/d,睡前服,治疗24周;对照组119例,予严格控制血糖和低脂饮食。测定2组治疗前后的血糖、TG、TC、LDL-C、HDL-C、hs-CRP、脂联素水平,并进行比较分析。结果治疗组用药后与用药前比较,血糖无明显改变,TG下降(P<0.05),HDL-C有升高的趋势,但差异无统计学意义,TC下降[(4.45±0.69)mmol/L比(6.88±1.61)mmol/L P<0.01],LDL-C下降[(2.42±0.89)mmol/L比(4.92±1.45)mmol/L,P<0.01],hs-CRP明显下降[(4.38±1.69)mg/L比(7.51±3.52)mg/L,P<0.01],脂联素升高[(24.32±10.52)mg/L比(14.97±11.39)mg/L,P<0.01]。与对照组治疗后比较,治疗组的TC、LDL-C、TG和hs-CRP明显降低,差异有统计学意义(P<0.05或P<0.01),脂联素升高,差异有统计学意义(P<0.01),血糖差异无统计学意义。结论瑞舒伐他汀钙可有效地改善糖尿病患者血脂异常和炎症状态,可明显减轻糖尿病患者的动脉粥样硬化程度,其抗炎作用机制可能与降低hs-CRP水平,升高血清脂联素水平有关。
Objective To observe the effect of rosuvastatin calcium on dyslipidemia in diabetic patients and its effect on high-sensitivity C-reactive protein (hs-CRP) and adiponectin. Methods 238 patients with diabetes mellitus and dyslipidemia were observed. Among them, 119 patients in the treatment group were given rosuvastatin calcium 10 mg / d on the basis of strict control of blood glucose and low-fat diet for 24 weeks before bedtime; Group 119 cases, to strictly control blood sugar and low-fat diet. The levels of blood glucose, TG, TC, LDL-C, HDL-C, hs-CRP and adiponectin in two groups before and after treatment were measured and compared. Results Compared with those before treatment, the blood glucose of the treatment group did not change significantly, TG decreased (P <0.05) and HDL-C increased, but the difference was not statistically significant. The TC decreased [(4.45 ± 0.69) mmol / L (2.42 ± 0.89) mmol / L (4.92 ± 1.45 mmol / L, P <0.01), hs-CRP decreased significantly compared with that of control group (6.88 ± 1.61 mmol / 1.69) mg / L (7.51 ± 3.52) mg / L, P <0.01], and adiponectin increased [(24.32 ± 10.52) mg / L vs 14.97 ± 11.39 mg / L, P <0.01]. Compared with the control group, TC, LDL-C, TG and hs-CRP in the treatment group were significantly lower, the difference was statistically significant (P <0.05 or P <0.01), adiponectin increased, the difference was statistically significant (P <0.01), no significant difference in blood glucose. Conclusion Rosuvastatin calcium can effectively improve the level of dyslipidemia and inflammation in diabetic patients, and can significantly reduce the degree of atherosclerosis in diabetic patients. The mechanism of anti-inflammatory may be related to the decrease of hs-CRP level and increase of serum adiponectin level related.